InflaRx closes USD55m Series D financing
InflaRx, a biopharmaceutical company developing new therapeutics in the terminal complement space, has closed a USD55 million Series D financing and investment round. The round was co-led by Bain Capital Life Sciences LP, Cormorant Asset Management LLC and RA Capital Management LLC, and complemented by certain investment funds managed by